This article is more than 5 years old. Information may no longer be current.
VIDEO: Debates abound in optimal management of ACS in both acute, chronic phases
Click Here to Manage Email Alerts
CHICAGO — Dominick J. Angiolillo, MD, PhD, director of CV research at the University of Florida College of Medicine in Jacksonville and Editorial Board member for Cardiology Today’s Intervention, provides insights on several debates surrounding the management of ACS.
“There are a lot of novelties in the field, and when we have new information there’s always room for debate,” he said.
Angiolillo discusses a reason for reservation in using the P2Y12 inhibitor cangrelor (Kengreal, The Medicines Company) — recently approved by the FDA and in Europe based on data from the CHAMPION PHOENIX trial — in routine clinical practice.
He also talks about considerations of opting for bivalirudin (Angiomax, The Medicines Company) vs. unfractionated heparin in patients with STEMI, an area debated since results of the HEAT-PPCI trial were released.
Angiolillo touches on questions around the treatment of choice during the maintenance phase of patients with ACS with regard to dual antiplatelet therapy, highlighting recently-released guidelines on duration.
Lastly, he discusses the role of adjunctive agents including the PAR-1 antagonist vorapaxar (Zontivity, Merck), also approved in the U.S. and Europe based on the TRA 2P-TIMI 50 trial, and concerns around triple therapy.